Zura Bio Limited

Equities

ZURA

KYG9TY5A1016

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
5.19 ^USD	+0.58%		+10.90%	+11.13%

May. 10	Oppenheimer Adjusts Zura Bio Price Target to $21 From $16, Maintains Outperform Rating	MT
May. 09	Zura Bio Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Zura Bio Limited Reports Earnings Results for the Full Year Ended December 31, 2023

March 28, 2024 at 06:03 am EDT

Zura Bio Limited reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 60.36 million. Basic loss per share from continuing operations was USD 2.09.

Latest news about Zura Bio Limited

Oppenheimer Adjusts Zura Bio Price Target to $21 From $16, Maintains Outperform Rating	May. 10	MT
Zura Bio Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Zura Bio Limited announced that it has received $112.4935 million in funding from a group of investors	May. 05	CI
Piper Sandler Starts Zura Bio With Overweight Rating, $26 Price Target	May. 03	MT
Zura Bio Insider Bought Shares Worth $499,999, According to a Recent SEC Filing	Apr. 25	MT
Zura Bio Insider Bought Shares Worth $3,715,000, According to a Recent SEC Filing	Apr. 25	MT
Zura Bio Expects To Raise About $112.5 Million in Gross Proceeds From Oversubscribed Private Placement	Apr. 18	MT
Zura Bio Limited announced that it expects to receive $112.4935 million in funding from a group of investors	Apr. 17	CI
Sector Update: Health Care Stocks Softer Monday Afternoon	Apr. 08	MT
Zura Bio Shares Rise After Robert Lisicki Assumes CEO Role	Apr. 08	MT
Oppenheimer Adjusts Zura Bio Price Target to $16 From $17, Maintains Outperform Rating	Apr. 01	MT
Zura Bio Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Zura Bio Limited Appoints Announces Chief Executive Officer Changes	Mar. 28	CI
Zura Bio Limited Appoints Lisicki as A Director of the Board	Mar. 28	CI
Zura Bio Limited Announces Executive Appointments	Jan. 08	CI
Zura Bio Insider Sold Shares Worth $8,000,000, According to a Recent SEC Filing	Dec. 14	MT
Zura Bio Limited Appoints Kiran Nistala as Executive Vice President	Dec. 06	CI
Zura Bio Announces Two Immunology Abstracts Presented At the World Allergy Congress in Bangkok	Dec. 04	CI
Zura Bio Limited Announces Board Changes	Nov. 14	CI
Zura Bio Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Ladenburg Thalmann Starts Zura Bio With Buy Rating, $10 Price Target	23-10-10	MT
Zura Bio Limited Appoints Parvinder Thiara to the Board	23-10-03	CI
Zura Bio Partners With Benaroya Research Institute for Research on Immune-Mediated Disorders	23-09-12	MT
Zura Bio Limited Enters into Sponsored Research Agreement with Benaroya Research Institute	23-09-12	CI
Oppenheimer Initiates Coverage on Zura Bio With Outperform Rating, $17 Price Target	23-08-25	MT

Chart Zura Bio Limited

Duration

Period

More charts

Company Profile

Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), ZB-168, and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other novel indications with unmet needs. Tibulizumab (ZB-106) is an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of TALTZ (ixekizumab) and tabalumab that neutralizes IL-17A and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain (IL-7R) alpha. Torudokimab (ZB-880) is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.

Sector

Biotechnology & Medical Research

Calendar

2024-08-11 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.05 USD

Average target price

17.8 USD

Spread / Average Target

+194.21%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ZURA BIO LIMITED	+11.13%	377M
VERTEX PHARMACEUTICALS INCORPORATED	+9.58%	115B
REGENERON PHARMACEUTICALS, INC.	+12.41%	106B
ARGENX SE	-2.59%	21.96B
BIONTECH SE	-12.38%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-3.35%	18.08B
WUXI APPTEC CO., LTD.	-38.57%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.51%	14.32B
SAREPTA THERAPEUTICS, INC.	+35.67%	12.42B

Bio Therapeutic Drugs